Why experts are criticizing FDA's approach to some neurological drugs
Listen now
Description
Some experts fear the FDA's accelerated approval process for neurological disease treatments greenlights clinically promising but unproven drugs that can result in giving patients false hope. Host Kelly Hooper talks with POLITICO health care reporter Katherine Ellen Foley about how the FDA is balancing those concerns against the needs of patients.
More Episodes
Artificial intelligence is changing the way doctors practice, but also how the health care business runs. Host Chelsea Cirruzzo talks with POLITICO health care reporter Daniel Payne about the ways AI is already used across the medical landscape and how regulators are responding.
Published 12/22/23
Published 12/22/23
As federal officials scramble to regulate artificial intelligence in health care, HHS has already become one of the top federal agencies using the technology. Host Kelly Hooper talks with POLITICO health reporter Chelsea Cirruzzo about some of the 80 implemented or planned uses of AI by HHS...
Published 12/21/23